Glial cell line-derived neurotrophic factor but not transforming growth factor β3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion

Proceedings of the National Academy of Sciences of the United States of America

Volumn 92, Issue 19, 1995, Pages 8935-8939

  Sauer, Hansjörg ^a   Rosenblad, Carl ^a   Björklund, Anders ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

neurodegeneration; Parkinson disease; substantia nigra

Indexed keywords

NEURITE PROMOTING FACTOR; NEUROTROPHIC FACTOR; OXIDOPAMINE; TRANSFORMING GROWTH FACTOR BETA3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; BRAIN PROTECTION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG MECHANISM; FEMALE; GLIA CELL; INTRACEREBRAL DRUG ADMINISTRATION; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROTROPISM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ADRENERGIC FIBERS; ANIMAL; COMPARATIVE STUDY; CORPUS STRIATUM; DOPAMINE; FEMALE; HISTOCYTOCHEMISTRY; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; NEURONS; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; RETROGRADE DEGENERATION; SUBSTANTIA NIGRA; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA;

EID: 0029047329     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.92.19.8935     Document Type: Article

References (40)